Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
7 recherche sur le mot-clé 'antipsychotics'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Antipsychotic Use and Metabolic Monitoring in Individuals with Developmental Disabilities Served in a Medicaid Medical Home / Lisa M. RUIZ in Journal of Autism and Developmental Disorders, 46-6 (June 2016)
[article]
Titre : Antipsychotic Use and Metabolic Monitoring in Individuals with Developmental Disabilities Served in a Medicaid Medical Home Type de document : Texte imprimé et/ou numérique Auteurs : Lisa M. RUIZ, Auteur ; Mackenzie DAMRON, Auteur ; Kyle B. JONES, Auteur ; Dean WEEDON, Auteur ; Paul S. CARBONE, Auteur ; Amanda V. BAKIAN, Auteur ; Deborah A. BILDER, Auteur Article en page(s) : p.1887-1894 Langues : Anglais (eng) Mots-clés : Antipsychotics Autism spectrum disorder Intellectual disability Medical home Index. décimale : PER Périodiques Résumé : This study describes antipsychotic use and metabolic monitoring rates among individuals with developmental disabilities enrolled in a subspecialty medical home (N = 826). Four hundred ninety-nine participants (60.4 %) were taking antipsychotics, which was associated with male gender (p = 0.01), intellectual disability with and without autism spectrum disorder (p = 0.001 and p = 0.04, respectively), and inversely associated with the youngest and oldest age categories (p = 0.001 and p = 0.04, respectively). Among those taking antipsychotics, annual metabolic monitoring rates ranged from 89 % (lipids) to 99 % (weight). Age was positively associated with glucose (p < 0.001) and lipid monitoring (p < 0.001). Adult participants with dyslipidemia (p < 0.01), prediabetes/diabetes (p = 0.04), and hypertension (p = 0.02) were significantly more likely to obtain lipid monitoring. These values exceeded previously reported rates suggesting the importance of an integrated care model. En ligne : http://dx.doi.org/10.1007/s10803-016-2712-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=288
in Journal of Autism and Developmental Disorders > 46-6 (June 2016) . - p.1887-1894[article] Antipsychotic Use and Metabolic Monitoring in Individuals with Developmental Disabilities Served in a Medicaid Medical Home [Texte imprimé et/ou numérique] / Lisa M. RUIZ, Auteur ; Mackenzie DAMRON, Auteur ; Kyle B. JONES, Auteur ; Dean WEEDON, Auteur ; Paul S. CARBONE, Auteur ; Amanda V. BAKIAN, Auteur ; Deborah A. BILDER, Auteur . - p.1887-1894.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 46-6 (June 2016) . - p.1887-1894
Mots-clés : Antipsychotics Autism spectrum disorder Intellectual disability Medical home Index. décimale : PER Périodiques Résumé : This study describes antipsychotic use and metabolic monitoring rates among individuals with developmental disabilities enrolled in a subspecialty medical home (N = 826). Four hundred ninety-nine participants (60.4 %) were taking antipsychotics, which was associated with male gender (p = 0.01), intellectual disability with and without autism spectrum disorder (p = 0.001 and p = 0.04, respectively), and inversely associated with the youngest and oldest age categories (p = 0.001 and p = 0.04, respectively). Among those taking antipsychotics, annual metabolic monitoring rates ranged from 89 % (lipids) to 99 % (weight). Age was positively associated with glucose (p < 0.001) and lipid monitoring (p < 0.001). Adult participants with dyslipidemia (p < 0.01), prediabetes/diabetes (p = 0.04), and hypertension (p = 0.02) were significantly more likely to obtain lipid monitoring. These values exceeded previously reported rates suggesting the importance of an integrated care model. En ligne : http://dx.doi.org/10.1007/s10803-016-2712-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=288 Characterization of Medication Use in a Multicenter Sample of Pediatric Inpatients with Autism Spectrum Disorder / L. K. WINK in Journal of Autism and Developmental Disorders, 48-11 (November 2018)
[article]
Titre : Characterization of Medication Use in a Multicenter Sample of Pediatric Inpatients with Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : L. K. WINK, Auteur ; Ernest V. PEDAPATI, Auteur ; R. ADAMS, Auteur ; C. A. ERICKSON, Auteur ; K. A. PEDERSEN, Auteur ; E. M. MORROW, Auteur ; Desmond KAPLAN, Auteur ; M. SIEGEL, Auteur Article en page(s) : p.3711-3719 Langues : Anglais (eng) Mots-clés : Antipsychotics Autism Autism Spectrum Disorder Medication Psychiatric hospitalization Index. décimale : PER Périodiques Résumé : Nearly 11% of youth with Autism Spectrum Disorder (ASD) undergo psychiatric hospitalization, and 65% are treated with psychotropic medication. Here we characterize psychotropic medication usage in subjects enrolled in the Autism Inpatient Collection. Participant psychotropic medication usage rates topped 90% at admission and discharge, though there was a decline at 2-month follow-up. Antipsychotics, ADHD medications, and sleep aids were the most commonly reported classes of medications. The impact of age, gender, and non-verbal IQ on medication usage rates was minimal, though age and IQ may play a role in prescribing practices. Future work is indicated to explore medication usage trends, the impact of clinical factors on medication use rates, and the safety of psychotropic medications in youth with ASD. En ligne : http://dx.doi.org/10.1007/s10803-017-3153-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=370
in Journal of Autism and Developmental Disorders > 48-11 (November 2018) . - p.3711-3719[article] Characterization of Medication Use in a Multicenter Sample of Pediatric Inpatients with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / L. K. WINK, Auteur ; Ernest V. PEDAPATI, Auteur ; R. ADAMS, Auteur ; C. A. ERICKSON, Auteur ; K. A. PEDERSEN, Auteur ; E. M. MORROW, Auteur ; Desmond KAPLAN, Auteur ; M. SIEGEL, Auteur . - p.3711-3719.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 48-11 (November 2018) . - p.3711-3719
Mots-clés : Antipsychotics Autism Autism Spectrum Disorder Medication Psychiatric hospitalization Index. décimale : PER Périodiques Résumé : Nearly 11% of youth with Autism Spectrum Disorder (ASD) undergo psychiatric hospitalization, and 65% are treated with psychotropic medication. Here we characterize psychotropic medication usage in subjects enrolled in the Autism Inpatient Collection. Participant psychotropic medication usage rates topped 90% at admission and discharge, though there was a decline at 2-month follow-up. Antipsychotics, ADHD medications, and sleep aids were the most commonly reported classes of medications. The impact of age, gender, and non-verbal IQ on medication usage rates was minimal, though age and IQ may play a role in prescribing practices. Future work is indicated to explore medication usage trends, the impact of clinical factors on medication use rates, and the safety of psychotropic medications in youth with ASD. En ligne : http://dx.doi.org/10.1007/s10803-017-3153-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=370 Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder / Jeanne M. MADDEN in Journal of Autism and Developmental Disorders, 47-1 (January 2017)
[article]
Titre : Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Jeanne M. MADDEN, Auteur ; Matthew D. LAKOMA, Auteur ; Frances L. LYNCH, Auteur ; Donna RUSINAK, Auteur ; Ashli A. OWEN-SMITH, Auteur ; Karen J. COLEMAN, Auteur ; Virginia P. QUINN, Auteur ; Vincent M. YAU, Auteur ; Yinge X. QIAN, Auteur ; Lisa A. CROEN, Auteur Article en page(s) : p.144-154 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Medications Antipsychotics Comorbidities Epidemiological studies Index. décimale : PER Périodiques Résumé : This study examined psychotropic medication use among 7901 children aged 1–17 with autism spectrum disorder (ASD) in five health systems, comparing to matched cohorts with no ASD. Nearly half (48.5?%) of children with ASD received psychotropics in the year observed; the most common classes were stimulants, alpha-agonists, or atomoxetine (30.2?%), antipsychotics (20.5?%), and antidepressants (17.8?%). Psychotropic treatment was far more prevalent among children with ASD, as compared to children with no ASD (7.7?% overall), even within strata defined by the presence or absence of other psychiatric diagnoses. The widespread use of psychotropics we observed, particularly given weak evidence supporting the effectiveness of these medications for most children with ASD, highlights challenges in ASD treatment and the need for greater investment in its evaluation. En ligne : http://dx.doi.org/10.1007/s10803-016-2946-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=298
in Journal of Autism and Developmental Disorders > 47-1 (January 2017) . - p.144-154[article] Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Jeanne M. MADDEN, Auteur ; Matthew D. LAKOMA, Auteur ; Frances L. LYNCH, Auteur ; Donna RUSINAK, Auteur ; Ashli A. OWEN-SMITH, Auteur ; Karen J. COLEMAN, Auteur ; Virginia P. QUINN, Auteur ; Vincent M. YAU, Auteur ; Yinge X. QIAN, Auteur ; Lisa A. CROEN, Auteur . - p.144-154.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 47-1 (January 2017) . - p.144-154
Mots-clés : Autism spectrum disorder Medications Antipsychotics Comorbidities Epidemiological studies Index. décimale : PER Périodiques Résumé : This study examined psychotropic medication use among 7901 children aged 1–17 with autism spectrum disorder (ASD) in five health systems, comparing to matched cohorts with no ASD. Nearly half (48.5?%) of children with ASD received psychotropics in the year observed; the most common classes were stimulants, alpha-agonists, or atomoxetine (30.2?%), antipsychotics (20.5?%), and antidepressants (17.8?%). Psychotropic treatment was far more prevalent among children with ASD, as compared to children with no ASD (7.7?% overall), even within strata defined by the presence or absence of other psychiatric diagnoses. The widespread use of psychotropics we observed, particularly given weak evidence supporting the effectiveness of these medications for most children with ASD, highlights challenges in ASD treatment and the need for greater investment in its evaluation. En ligne : http://dx.doi.org/10.1007/s10803-016-2946-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=298 Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders / R. HOUGHTON in Autism Research, 14-8 (August 2021)
[article]
Titre : Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders Type de document : Texte imprimé et/ou numérique Auteurs : R. HOUGHTON, Auteur ; J. VAN DEN BERGH, Auteur ; K. LAW, Auteur ; Y. LIU, Auteur ; F. DE VRIES, Auteur Article en page(s) : p.1800-1814 Langues : Anglais (eng) Mots-clés : Adolescent Antipsychotic Agents/adverse effects Aripiprazole/adverse effects Autism Spectrum Disorder/complications/drug therapy/epidemiology Child Cohort Studies Female Fractures, Bone/drug therapy/epidemiology Humans Male Retrospective Studies Risperidone/adverse effects United States/epidemiology antipsychotics aripiprazole autism spectrum disorder fractures risperidone Index. décimale : PER Périodiques Résumé : Risperidone and aripiprazole, commonly used antipsychotics in children with autism spectrum disorder (ASD), have previously been associated with elevated fracture risk in other populations. The aim of this study was to evaluate and compare the risk of fracture among children with ASD using risperidone or aripiprazole. This was a retrospective, propensity-score matched cohort study, set between January 2013 and December 2018. We used the MarketScan Medicaid insurance data, which covers multiple states of the United States. We included ASD children aged 2-18?years, who were new users of aripiprazole or risperidone and with no prior history of antipsychotic use or fractures. The main exposure was the continued use of aripiprazole or risperidone. The incidence rates of any fracture during follow-up were evaluated, and the risk between aripiprazole and risperidone was compared via Cox-proportional hazard models. Results were stratified by age, sex, duration of exposure and fracture site. In total, 3312 patients (78% male; mean [SD] age 11.0 [3.7] years) were identified for each cohort. Over the full duration of follow-up, fracture incidence rates per 1000 patient-years were 23.2 for risperidone and 38.4 for aripiprazole (hazard ratio and 95% confidence interval: 0.60 [0.44-0.83]). Risks were similar between cohorts throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. Extremity fractures drove most of the increased risk, with the biggest differences in lower leg and ankle fractures. Differences widened for children aged 10?years or younger (HR [95% CI]: 0.47 [0.30-0.74]). In conclusion, compared to aripiprazole, risperidone was associated with 40% lower risk of fracture. Further analysis on the mechanism and long-term bone health of antipsychotic-treated children with ASD is warranted. LAY SUMMARY: We compared the risk of bone fractures among 6624 children with autism spectrum disorder (ASD), half of whom used risperidone and half of whom used aripiprazole. Taking other factors into account, risks were similar between the two groups throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. The biggest differences were in lower leg and ankle fractures. Overall, compared with aripiprazole, risperidone was associated with 40% lower risk of fracture. En ligne : http://dx.doi.org/10.1002/aur.2541 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449
in Autism Research > 14-8 (August 2021) . - p.1800-1814[article] Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders [Texte imprimé et/ou numérique] / R. HOUGHTON, Auteur ; J. VAN DEN BERGH, Auteur ; K. LAW, Auteur ; Y. LIU, Auteur ; F. DE VRIES, Auteur . - p.1800-1814.
Langues : Anglais (eng)
in Autism Research > 14-8 (August 2021) . - p.1800-1814
Mots-clés : Adolescent Antipsychotic Agents/adverse effects Aripiprazole/adverse effects Autism Spectrum Disorder/complications/drug therapy/epidemiology Child Cohort Studies Female Fractures, Bone/drug therapy/epidemiology Humans Male Retrospective Studies Risperidone/adverse effects United States/epidemiology antipsychotics aripiprazole autism spectrum disorder fractures risperidone Index. décimale : PER Périodiques Résumé : Risperidone and aripiprazole, commonly used antipsychotics in children with autism spectrum disorder (ASD), have previously been associated with elevated fracture risk in other populations. The aim of this study was to evaluate and compare the risk of fracture among children with ASD using risperidone or aripiprazole. This was a retrospective, propensity-score matched cohort study, set between January 2013 and December 2018. We used the MarketScan Medicaid insurance data, which covers multiple states of the United States. We included ASD children aged 2-18?years, who were new users of aripiprazole or risperidone and with no prior history of antipsychotic use or fractures. The main exposure was the continued use of aripiprazole or risperidone. The incidence rates of any fracture during follow-up were evaluated, and the risk between aripiprazole and risperidone was compared via Cox-proportional hazard models. Results were stratified by age, sex, duration of exposure and fracture site. In total, 3312 patients (78% male; mean [SD] age 11.0 [3.7] years) were identified for each cohort. Over the full duration of follow-up, fracture incidence rates per 1000 patient-years were 23.2 for risperidone and 38.4 for aripiprazole (hazard ratio and 95% confidence interval: 0.60 [0.44-0.83]). Risks were similar between cohorts throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. Extremity fractures drove most of the increased risk, with the biggest differences in lower leg and ankle fractures. Differences widened for children aged 10?years or younger (HR [95% CI]: 0.47 [0.30-0.74]). In conclusion, compared to aripiprazole, risperidone was associated with 40% lower risk of fracture. Further analysis on the mechanism and long-term bone health of antipsychotic-treated children with ASD is warranted. LAY SUMMARY: We compared the risk of bone fractures among 6624 children with autism spectrum disorder (ASD), half of whom used risperidone and half of whom used aripiprazole. Taking other factors into account, risks were similar between the two groups throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. The biggest differences were in lower leg and ankle fractures. Overall, compared with aripiprazole, risperidone was associated with 40% lower risk of fracture. En ligne : http://dx.doi.org/10.1002/aur.2541 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449 Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis / R. RODRIGUES in Journal of Child Psychology and Psychiatry, 62-6 (June 2021)
[article]
Titre : Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis Type de document : Texte imprimé et/ou numérique Auteurs : R. RODRIGUES, Auteur ; Meng-Chuan LAI, Auteur ; A. BESWICK, Auteur ; D. A. GORMAN, Auteur ; Evdokia ANAGNOSTOU, Auteur ; P. SZATMARI, Auteur ; K. K. ANDERSON, Auteur ; Stephanie H. AMEIS, Auteur Article en page(s) : p.680-700 Langues : Anglais (eng) Mots-clés : Adolescent Atomoxetine Hydrochloride/therapeutic use Attention Deficit Disorder with Hyperactivity/drug therapy Autism Spectrum Disorder/drug therapy Central Nervous System Stimulants/adverse effects Child Guanfacine Humans Methylphenidate/adverse effects Adhd Attention-deficit/hyperactivity disorder alpha-2 agonists antipsychotics atomoxetine autism spectrum disorder bupropion hyperactivity impulsivity inattention modafinil. pervasive developmental disorder pharmacotherapy stimulants tricyclic antidepressants venlafaxine Index. décimale : PER Périodiques Résumé : BACKGROUND: Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD). The aim of this systematic review and meta-analysis was to (a) evaluate the efficacy and safety of pharmacotherapy for the treatment of ADHD symptoms in ASD and (b) distil findings for clinical translation. METHODS: We searched electronic databases and clinical trial registries (1992 onwards). We selected randomized controlled trials conducted in participants <25 years of age, diagnosed with ASD that evaluated ADHD outcomes (hyperactivity/impulsivity and inattention) following treatment with stimulants (methylphenidate or amphetamines), atomoxetine, alpha-2 adrenergic receptor agonists, antipsychotics, tricyclic antidepressants, bupropion, modafinil, venlafaxine, or a combination, in comparison with placebo, any of the listed medications, or behavioral therapies. Data were pooled using a random-effects model. RESULTS: Twenty-five studies (4 methylphenidate, 4 atomoxetine, 1 guanfacine, 14 antipsychotic, 1 venlafaxine, and 1 tianeptine) were included. Methylphenidate reduced hyperactivity (parent-rated: standardized mean difference [SMD] = -.63, 95%CI = -.95,-.30; teacher-rated: SMD = -.81, 95%CI = -1.43,-.19) and inattention (parent-rated: SMD = -.36, 95%CI = -.64,-.07; teacher-rated: SMD = -.30, 95%CI = -.49,-.11). Atomoxetine reduced inattention (parent-rated: SMD = -.54, 95%CI = -.98,-.09; teacher/investigator-rated: SMD = -0.38, 95%CI = -0.75, -0.01) and parent-rated hyperactivity (parent-rated: SMD = -.49, 95%CI = -.76,-.23; teacher-rated: SMD = -.43, 95%CI = -.92, .06). Indirect evidence for significant reductions in hyperactivity with second-generation antipsychotics was also found. Quality of evidence for all interventions was low/very low. Methylphenidate was associated with a nonsignificant elevated risk of dropout due to adverse events. CONCLUSIONS: Direct pooled evidence supports the efficacy and tolerability of methylphenidate or atomoxetine for treatment of ADHD symptoms in children and youth with ASD. The current review highlights the efficacy of standard ADHD pharmacotherapy for treatment of ADHD symptoms in children and youth with ASD. Consideration of the benefits weighed against the limitations of safety/efficacy data and lack of data evaluating long-term continuation is undertaken to help guide clinical decision-making regarding treatment of co-occurring ADHD symptoms in children and youth with ASD. En ligne : http://dx.doi.org/10.1111/jcpp.13305 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=455
in Journal of Child Psychology and Psychiatry > 62-6 (June 2021) . - p.680-700[article] Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis [Texte imprimé et/ou numérique] / R. RODRIGUES, Auteur ; Meng-Chuan LAI, Auteur ; A. BESWICK, Auteur ; D. A. GORMAN, Auteur ; Evdokia ANAGNOSTOU, Auteur ; P. SZATMARI, Auteur ; K. K. ANDERSON, Auteur ; Stephanie H. AMEIS, Auteur . - p.680-700.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 62-6 (June 2021) . - p.680-700
Mots-clés : Adolescent Atomoxetine Hydrochloride/therapeutic use Attention Deficit Disorder with Hyperactivity/drug therapy Autism Spectrum Disorder/drug therapy Central Nervous System Stimulants/adverse effects Child Guanfacine Humans Methylphenidate/adverse effects Adhd Attention-deficit/hyperactivity disorder alpha-2 agonists antipsychotics atomoxetine autism spectrum disorder bupropion hyperactivity impulsivity inattention modafinil. pervasive developmental disorder pharmacotherapy stimulants tricyclic antidepressants venlafaxine Index. décimale : PER Périodiques Résumé : BACKGROUND: Clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms are common and impairing in children and youth with autism spectrum disorder(ASD). The aim of this systematic review and meta-analysis was to (a) evaluate the efficacy and safety of pharmacotherapy for the treatment of ADHD symptoms in ASD and (b) distil findings for clinical translation. METHODS: We searched electronic databases and clinical trial registries (1992 onwards). We selected randomized controlled trials conducted in participants <25 years of age, diagnosed with ASD that evaluated ADHD outcomes (hyperactivity/impulsivity and inattention) following treatment with stimulants (methylphenidate or amphetamines), atomoxetine, alpha-2 adrenergic receptor agonists, antipsychotics, tricyclic antidepressants, bupropion, modafinil, venlafaxine, or a combination, in comparison with placebo, any of the listed medications, or behavioral therapies. Data were pooled using a random-effects model. RESULTS: Twenty-five studies (4 methylphenidate, 4 atomoxetine, 1 guanfacine, 14 antipsychotic, 1 venlafaxine, and 1 tianeptine) were included. Methylphenidate reduced hyperactivity (parent-rated: standardized mean difference [SMD] = -.63, 95%CI = -.95,-.30; teacher-rated: SMD = -.81, 95%CI = -1.43,-.19) and inattention (parent-rated: SMD = -.36, 95%CI = -.64,-.07; teacher-rated: SMD = -.30, 95%CI = -.49,-.11). Atomoxetine reduced inattention (parent-rated: SMD = -.54, 95%CI = -.98,-.09; teacher/investigator-rated: SMD = -0.38, 95%CI = -0.75, -0.01) and parent-rated hyperactivity (parent-rated: SMD = -.49, 95%CI = -.76,-.23; teacher-rated: SMD = -.43, 95%CI = -.92, .06). Indirect evidence for significant reductions in hyperactivity with second-generation antipsychotics was also found. Quality of evidence for all interventions was low/very low. Methylphenidate was associated with a nonsignificant elevated risk of dropout due to adverse events. CONCLUSIONS: Direct pooled evidence supports the efficacy and tolerability of methylphenidate or atomoxetine for treatment of ADHD symptoms in children and youth with ASD. The current review highlights the efficacy of standard ADHD pharmacotherapy for treatment of ADHD symptoms in children and youth with ASD. Consideration of the benefits weighed against the limitations of safety/efficacy data and lack of data evaluating long-term continuation is undertaken to help guide clinical decision-making regarding treatment of co-occurring ADHD symptoms in children and youth with ASD. En ligne : http://dx.doi.org/10.1111/jcpp.13305 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=455 Practitioner Review: Treatment of Schizophrenia in Childhood and Adolescence / Andrew F. CLARK in Journal of Child Psychology and Psychiatry, 39-8 (November 1998)
PermalinkA preliminary study of pharmacogenetic biomarkers for individuals with autism and gastrointestinal dysfunction / A. E. SHINDLER in Research in Autism Spectrum Disorders, 71 (March 2020)
Permalink